PARADIGM-HF

PARADIGM-HF
Name	PARADIGM-HF
Full name	Prospective comparison of ARNI with ACE inhibitor to Determine Impact on Global Mortality and morbidity in Heart Failure
Acronym	PARADIGM-HF
Phase	Phase III
Condition	Heart failure
Interventions	Sacubitril/valsartan vs enalapril
Sponsor	Novartis
Start date	2009
Completion date	2014
Participants	8399
Primary outcome	Composite of death from cardiovascular causes or first hospitalization for heart failure

PARADIGM-HF

PARADIGM-HF was a large, multicenter, randomized, double-blind, active-controlled trial testing sacubitril/valsartan against enalapril in patients with chronic heart failure and reduced ejection fraction, enrolling 8,399 participants and reported in 2014. The trial, led by investigators affiliated with institutions including Harvard Medical School, University of Glasgow, and sponsored by Novartis, influenced guideline updates from organizations such as the American College of Cardiology, European Society of Cardiology, and American Heart Association. Results were presented at meetings of the European Society of Cardiology and published simultaneously in The New England Journal of Medicine and cited by regulatory agencies including the U.S. Food and Drug Administration and the European Medicines Agency.

Background

The trial arose from translational research integrating neprilysin inhibition and renin–angiotensin–aldosterone system blockade after preclinical work at institutions like Massachusetts General Hospital, Stanford University, and University of Pennsylvania demonstrated combined pathway modulation could affect cardiac remodeling, neurohormonal activation, and outcomes in heart failure models. Key prior clinical studies by groups at Duke University, University of Oxford, and Mayo Clinic had established mortality benefits for angiotensin-converting enzyme inhibitors and beta-blockers, motivating comparison with a novel angiotensin receptor–neprilysin inhibitor developed by Novartis and tested amid regulatory discussions involving the European Medicines Agency and U.S. Food and Drug Administration. Thought leaders including investigators associated with Yale School of Medicine, Johns Hopkins University, and Imperial College London contributed to protocol design framed by guidance from the World Health Organization and standards used in trials such as those by MERIT-HF and SOLVD.

Trial Design and Methods

PARADIGM-HF was a randomized, double-blind, parallel-group, active-controlled, event-driven Phase III trial coordinated through academic centers including Brigham and Women's Hospital, Cleveland Clinic, and Guy's and St Thomas' NHS Foundation Trust. The protocol required run-in periods using open-label agents at centers affiliated with McMaster University, University of Toronto, and University College London to assess tolerability before randomization, with statistical oversight by groups experienced with trials such as CHARM and RALES. Primary and secondary endpoints were adjudicated by committees modeled on adjudication processes used by ClinicalTrials.gov-registered cardiovascular trials, with data monitoring by independent boards reflecting practices at World Health Organization-endorsed trial networks.

Participants and Baseline Characteristics

Enrollees were adults with chronic heart failure and reduced ejection fraction recruited from more than 970 sites across countries including the United States, United Kingdom, Canada, Brazil, China, Japan, and Australia. Baseline characteristics reflected prior heart failure cohorts studied at Duke Clinical Research Institute and Stanford University School of Medicine, showing median age in the mid-60s, predominance of male participants previously treated with beta-blockers and mineralocorticoid receptor antagonists per patterns seen in registries from European Society of Cardiology member centers and the American Heart Association Get With The Guidelines program. Comorbidities mirrored global heart failure populations described by investigators from Mayo Clinic, Columbia University, and University of Washington.

Interventions and Procedures

Participants underwent sequential run-in dosing with enalapril and sacubitril/valsartan using titration schemes developed by pharmacology groups at Novartis and academic pharmacology units linked to Johns Hopkins University School of Medicine. Randomization allocated subjects to sacubitril/valsartan (target dose 200 mg twice daily) or enalapril (target dose 10 mg twice daily), with concomitant guideline-directed therapies such as beta-blockers and mineralocorticoid receptor antagonists consistent with recommendations from the European Society of Cardiology and American College of Cardiology. Follow-up visits and event ascertainment were performed at clinical sites modeled after networks coordinated by Duke University Medical Center and data captured using systems similar to those at ClinicalTrials.gov-registered multicenter trials.

Outcomes and Results

The primary composite outcome—death from cardiovascular causes or first hospitalization for heart failure—was reduced with sacubitril/valsartan versus enalapril, with a hazard reduction that led to early trial stoppage after independent monitoring similar to precedents at Duke Clinical Research Institute and adjudicated outcomes echoing methods used in SOLVD and CHARM. Secondary outcomes, including all-cause mortality and heart-failure hospitalization rates, favored sacubitril/valsartan, consistent with effect sizes prompting guideline changes by the American Heart Association, European Society of Cardiology, and inclusion in reviews by the U.S. Food and Drug Administration and National Institute for Health and Care Excellence.

Safety and Adverse Events

Safety analyses reported differences in adverse event profiles, with higher rates of symptomatic hypotension but lower rates of renal dysfunction and cough compared with enalapril, findings that were interpreted in light of safety frameworks from World Health Organization pharmacovigilance and postmarketing surveillance conducted by Novartis and assessed by regulators including the European Medicines Agency and the U.S. Food and Drug Administration. Serious adverse event monitoring followed standards applied in trials overseen by institutions such as Brigham and Women's Hospital and Mayo Clinic.

Interpretation and Impact on Clinical Practice

The trial's positive results led to rapid integration of sacubitril/valsartan into treatment algorithms promulgated by the American College of Cardiology, American Heart Association, and European Society of Cardiology, influenced formulary decisions in health systems such as the National Health Service (England), and prompted cost-effectiveness analyses conducted by groups at Harvard T.H. Chan School of Public Health, London School of Economics, and University of Toronto. Subsequent pragmatic studies and registries from centers including Cleveland Clinic, Mount Sinai Health System, and Singapore General Hospital have evaluated real-world implementation, while ongoing research at institutions like Stanford University and University of Oxford continues to refine patient selection and long-term outcomes.

Category:Clinical trials